What is the recommended management for macroalbuminuria (albumin‑creatinine ratio >300 mg/g)?

Management of Macroalbuminuria (Albumin-Creatinine Ratio >300 mg/g)

Start an ACE inhibitor or ARB immediately—this is a Grade A recommendation for patients with urinary albumin excretion >300 mg/day and is the cornerstone of preventing progression to end-stage renal disease. 1

Core Treatment Algorithm

1. Initiate Renin-Angiotensin System Blockade

• ACE inhibitor OR ARB (not both—combination therapy increases adverse events including hyperkalemia and acute kidney injury without added benefit) 2
• This is mandatory therapy with Level A evidence for albumin excretion >300 mg/g 1
• Titrate to maximum tolerated dose to maximize albuminuria reduction 3

2. Optimize Glycemic Control

• Target near-normoglycemia (HbA1c <7% in most patients) 1
• Large prospective trials demonstrate this delays progression of diabetic kidney disease 1
• Important caveat: In patients with advanced CKD and substantial comorbidity, less intensive glycemic targets may be appropriate due to increased hypoglycemia risk and mortality seen in trials like ACCORD 4

3. Optimize Blood Pressure Control

• Target <130/80 mmHg 1
• Use ACE inhibitor or ARB as first-line agent 2
• Add additional antihypertensive agents as needed to reach target

4. Consider Adding Newer Agents

SGLT2 Inhibitors:

• Reduce albuminuria, slow GFR decline, and lower cardiovascular risk through mechanisms independent of glycemia 4, 3
• Can be initiated with eGFR ≥20 mL/min/1.73 m² (varies by agent)

Non-steroidal Mineralocorticoid Receptor Antagonist (Finerenone):

• Add finerenone for patients with persistent albuminuria despite ACE inhibitor/ARB therapy 2
• Start at 20 mg daily if eGFR >60 mL/min/1.73 m², or 10 mg daily if eGFR 25-60 mL/min/1.73 m²
• Requires potassium ≤5.0 mmol/L at initiation 2
• Provides additional cardiorenal protection beyond standard RAS blockade

Monitoring Requirements

Laboratory Surveillance:

• Monitor serum creatinine and potassium within 1-2 weeks after starting or adjusting ACE inhibitor, ARB, or mineralocorticoid receptor antagonist 1, 3
• Accept creatinine increases up to 30% without discontinuing RAS blockade (unless accompanied by hyperkalemia) 3
• Recheck UACR within 6 months to assess treatment response 3
  • Goal: Reduce UACR by ≥30% from baseline—this is associated with improved renal and cardiovascular outcomes 4, 3
  • If no reduction achieved, verify blood pressure targets are met and maximize RAS blockade dosing

Ongoing Monitoring:

• Annual UACR and eGFR assessment at minimum 1, 3
• More frequent monitoring (every 3-6 months) if eGFR <60 mL/min/1.73 m² 4

Additional Management Considerations

When eGFR <60 mL/min/1.73 m²:

• Evaluate and manage CKD complications (anemia, metabolic bone disease, electrolyte abnormalities, volume overload) 1, 4
• Verify appropriate medication dosing 4
• Minimize nephrotoxin exposure (NSAIDs, iodinated contrast) 4, 3

Nephrology Referral Indications:

• Uncertainty about kidney disease etiology 1
• Difficulty managing hypertension or albuminuria 5
• eGFR <30 mL/min/1.73 m² 1
• Rapidly progressive disease 5

Dietary Modifications:

• Maintain protein intake at 0.8 g/kg/day (the recommended daily allowance) 1, 3
• Do NOT restrict protein below this level—it does not improve outcomes 1
• Consider modest protein restriction only if disease progresses despite optimal medical therapy 1

Critical Pitfalls to Avoid

1. Do not combine ACE inhibitor + ARB—this increases harm without benefit 2
2. Do not discontinue RAS blockade for creatinine increases <30% (unless hyperkalemia develops) 3
3. Do not use olmesartan in patients with pre-existing cardiovascular disease—unexpected higher fatal cardiovascular events reported 1
4. Avoid pregnancy while on ACE inhibitors or ARBs—these are contraindicated 1
5. Monitor potassium closely when using RAS blockade, especially when adding mineralocorticoid receptor antagonists 1, 2